Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPECT CT Performance in Metastatic Prostate Cancer
NCT03619655Phase 1Terminated
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Nov 2019
- Primary completion
- Nov 2022
- Countries
- 1
01
Overview
Phase 1, open-label trial in prostate cancer (PCa) and metastatic castration-resistant prostate cancer (mCRPC) (3 cohorts), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Accuracy for Prediction of Progression Free Survival as determined by Quantitative bone SPECT indices (QBSIs). Started Nov 2019; status: terminated.
02
Conditions
prostate cancer (PCa)metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03619655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03619655.